Retrospective Analysis of the Four Seasons Antiviral Admixture in the Treatment of SARS-CoV-2 Infection in Children

Abstract

Objective: To conduct a retrospective analysis, evaluate the clinical efficacy of the four seasons antiviral admixture, and provide clinical basis for the treatment of novel coronavirus infection in children. Methods: Using a clinical retrospective study method, A total of 102 children from the Second Affiliated Hospital of Shaanxi University of Chinese Medicine who met the diagnostic criteria of pediatric SARS-CoV-2 were collected, Randomized into control group (conventional western medicine treatment), 51 cases in the observation group (using four seasons antiviral admixture in the control group), Compare the changes of fever duration, the duration of cough, hospital stay, and before and after treatment (white ocyte count, percentage, percentage of lymphocytes, monocytes, C reactive protein, interleukin-6, sedimentation rate, creatine kinase isoenzyme, myoglobin, hypersensitive troponin I). Results: The cure rate was 76.47%, significantly higher than that of the control group (P <0.05); the difference between fever and duration of cough and hospitalization days in the observation and control groups (P <0.05); WBC count, central cell percentage, monocyte percentage, C reactive protein, interleukin-6, blood loss, increase of lymphocyte percentage and the difference (P <0.05); and no adverse events occurred after treatment. Conclusion: Four seasons antiviral admixture can significantly shorten the duration of fever, cough and hospitalization in children with novel coronavirus infection, effectively improve the infection index and myocardial injury index in children, and be safe and reliable.